[{"id":"26ef985f-26c3-4561-a72c-4b31906080ac","acronym":"HAMMER","url":"https://clinicaltrials.gov/study/NCT04009681","created_at":"2021-11-23T17:53:44.333Z","updated_at":"2024-07-02T16:35:11.315Z","phase":"Phase 1/2","brief_title":"A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)","source_id_and_acronym":"NCT04009681 - HAMMER","lead_sponsor":"Synthorx, Inc, a Sanofi company","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • pegenzileukin (SAR444245)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 06/20/2019","start_date":" 06/20/2019","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-04-05"}]